Pneumocystis jirovecii is a pathogen that causes severe illness and even death for people who are immunocompromised due to solid organ transplantation. When the organism is inhaled by an immunocompromised individual, infection can occur. The infection may lead to Pneumocystis pneumonia (PCP), which can be passed from person-to-person in medical settings. Unfortunately, PCP has been seen to occur more than a year after organ transplantation, and higher rates have been reported in patients who have received heart, lung, and combined heart-lung transplants.
In the article, “Current Concepts in the Diagnosis and Management of Pneumocystis Pneumonia in Solid Organ Transplantation,” infectious disease specialists Paul Trubin, MD, and Marwan Azar, MD, FAST, FIDSA, explore the epidemiology of Pneumocystis jirovecii, share the clinical presentations of the pathogen, outline the steps to diagnose PCP, and walk through the treatment options for the disease, with a particular focus on organ transplant recipients.
This review arms healthcare providers with the information needed to make robust care decisions. Learn more in Infectious Disease Clinics of North America.
Trubin P, Azar M. Current Concepts in the Diagnosis and Management of Pneumocystis Pneumonia in Solid Organ Transplantation. Infectious Disease Clinics Of North America 2023 PMID: 37142510, DOI: 10.1016/j.idc.2023.03.005.
Discoveries & Impact highlights select scientific discoveries across the Department of Internal Medicine. To read more about the recently released research, click on a link under Related Links.